IGO:ASXIGO Limited Analysis
Data as of 2026-08-21 - not real-time
A$8.36
Latest Price
8/10Risk
Risk Level: High
Executive Summary
IGO Limited is priced at AUD 8.36, and its moving averages give no clean directional read — the structure is neutral. Across the trailing 30 sessions it gained 21.3%. RSI sits at 67.4, which reads as approaching overbought, and MACD momentum is bullish. Watch AUD 6.65 as support and AUD 8.40 as the nearer resistance level.
Valuation screens as overvalued, on a P/E of 13.4 with no clean sector comparison available. Consensus targets land 7.8% below where the shares trade now. Revenue is contracting at 31.7% on a -47.2% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 40.2%, a beta of 0.88 and a maximum drawdown of 35.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
Valuation screens as overvalued, on a P/E of 13.4 with no clean sector comparison available. Consensus targets land 7.8% below where the shares trade now. Revenue is contracting at 31.7% on a -47.2% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 40.2%, a beta of 0.88 and a maximum drawdown of 35.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
Top Market Events
IGO Ltd posts 18% surge in Q4 sales revenue, growing cash reserves and strong results at Nova and Greenbushes.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading above the 200-day average of 7.86
- MACD momentum is positive
- 30-day price change of +21.3%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Trading above the 200-day average of 7.86
- Analyst targets imply -7.8% versus the current price
- 30-day volatility of 40.2%
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Negative profit margin of -47.2%
- Analyst targets imply -7.8% versus the current price
- Negative return on equity of -9.5%
Key Metrics & Analysis
Financial Health
Revenue Growth-31.70%
Profit Margin-47.18%
P/E Ratio13.4
ROE-9.54%
ROA-4.48%
Debt/Equity1.02
P/B Ratio3.1
Op. Cash FlowA$78.0M
Free Cash FlowA$169.3M
Technical Analysis
TrendNeutral
RSI67.4
SupportA$6.65
ResistanceA$8.40
MA 20A$7.50
MA 50A$7.43
MA 200A$7.86
MACDBullish
VolumeDecreasing
Fear & Greed Index94.09
Valuation
Fair ValueA$3.39
Target PriceA$7.71
Upside/Downside-7.77%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.88
Volatility40.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.